Toll-Like Receptor Signaling in Neuroinflammation and Neurodegeneration

Toll-like receptors (TLRs) are a family of evolutionarily conserved pattern-recognition receptors that orchestrate the innate immune response in the central nervous system. Expressed on microglia, astrocytes and neurons, TLRs detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) such as amyloid-β, tau oligomers or exogenous viral proteins. Activation of TLRs engages adapter proteins including MyD88 and TRIF, leading to downstream NF-κB and IRF3 signalling cascades and the release of cytokines, chemokines and other mediators that shape the neuroinflammatory milieu. While acute TLR-driven inflammation may promote clearance of pathogens and toxic aggregates, chronic or dysregulated signalling contributes to synaptic dysfunction, neuronal loss and the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Recent mechanistic insights have revealed complex crosstalk between TLRs and complement, the NLRP3 inflammasome and metabolic pathways, highlighting a multifaceted regulatory network. Genetic variants affecting TLR9, for instance, modulate microglial phagocytosis of amyloid-β, whereas TLR2 and TLR4 recognise pathogenic tau and drive injurious microglial activation. Pharmacological interventions targeting these pathways – from small-molecule antagonists to monoclonal antibodies – show promise in preclinical models, signalling a transition towards precision immunomodulation in neurodegenerative disease. Global efforts continue to unravel context-dependent TLR functions, aiming to harness beneficial neuroimmune interactions while restraining chronic neuroinflammation.

Research from Nature Portfolio

Recent studies have illuminated the role of a damage-associated molecular pattern in neurite degeneration mediated by TLR4. Researchers demonstrated that HMGB1 released from damaged neurons binds to TLR4, triggers MARCKS phosphorylation via MAP kinases and precipitates neurite collapse prior to amyloid deposition. An anti-HMGB1 monoclonal antibody administered peripherally effectively prevented neurite loss and restored cognition in a mouse model, highlighting a novel immunotherapeutic approach to arrest early neurodegeneration.

Toll-Like Receptor Signaling in Neuroinflammation and Neurodegeneration publication trend

The graph below shows the total number of articles in toll-like receptor signaling in neuroinflammation and neurodegeneration across all publications each year (not limited to Nature Index journals).

Technical terms

Toll-like receptor (TLR): Family of pattern-recognition receptors that detect pathogen-associated or damage-associated molecular patterns and initiate innate immune signalling.

Neuroinflammation: Immune response within the central nervous system characterised by glial activation and production of proinflammatory mediators.

Microglia: Resident immune cells of the brain that mediate phagocytosis and cytokine release in response to injury or pathogens.

Damage-associated molecular pattern (DAMP): Endogenous molecules released from damaged or dying cells that trigger innate immune receptors.

MyD88: Key cytosolic adaptor that couples most TLRs to downstream signalling cascades leading to NF-κB activation and cytokine production.

Monoclonal antibody: Laboratory-generated antibody targeting a specific antigen, used therapeutically to neutralise or block receptor function.

References

1. Mutated Toll-like receptor 9 increases Alzheimer’s disease risk by compromising innate immunity protection. Molecular Psychiatry (2023).
2. TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease. Frontiers in Immunology (2020).
3. HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer’s disease. Scientific Reports (2016).
4. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behavior and Immunity (2024).
5. A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice. Alzheimer's Research & Therapy (2023).